Erlotinib (Tarceva): Potent HER1/epidermal growth factor receptor inhibition: Introduction

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)1-2
Number of pages2
JournalSeminars in oncology
Volume30
Issue number3 SUPPL. 7
DOIs
StatePublished - Jun 2003

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this